- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00952562
The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals
August 23, 2011 updated by: Zealand University Hospital
The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals. A Randomised Double Blinded Placebo Controlled Trial.
A randomized placebo controlled trial evaluating the effect of the recently recommended high doses of cholecalciferol (3000 IU/day) on mineral metabolism, blood pressure and pulse wave analysis in healthy individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Roskilde, Denmark, 4000
- Roskilde Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- > 18 years old
- p 25OH vitaminD<50nmol/l
- signed informed consent
Exclusion Criteria:
- receiving antihypertensive or antidiabetic treatment
- sarcoidoses
- history of kidney stones
- receiving 1-alfa-hydroxylated vitamin D treatment
- plasma creatinin > 120 micromol/l
- ionised calcium > 1,5 mmol/l
- treatment with calcimimetics
- active malignancy
- intestinal malabsorption
- active pancreatitis
- former hospitalisation due to alcoholic related disease
- using euphoriant drugs
- pregnancy or risk of being pregnant or lactating women
- Known allergy to cholecalciferol capsules
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
Empty capsules, 3 capsules per day for 16 weeks
|
|
Active Comparator: cholecalciferol
3000 IU cholecalciferol per day for 16 weeks
|
Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
urinary calcium excretion
Time Frame: before and after 16 weeks of intervention
|
before and after 16 weeks of intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
25 hydroxyvitamin D
Time Frame: before and after 16 weeks og treatment
|
before and after 16 weeks og treatment
|
|
1,25 dihydroxyvitamin D
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
urinary creatinin
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
urinary protein
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
urinary phosphorous
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
p-FGF23
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
blood pressure
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
pulse wave velocity
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
augmentation index
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
central blood pressure
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
p-phosphate
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
ionised p-calcium
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
p-iPTH
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
|
alkalic phosphatase
Time Frame: before and after 16 weeks of treatment
|
before and after 16 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ditte Hansen, MD, Zealand University Hospital
- Principal Investigator: Niels Erik Frandsen, MD, Zealand University Hospital
- Principal Investigator: Knud Rasmussen, DmSci, Zealand University Hospital
- Principal Investigator: Lisbet Brandi, DmSci, Zealand University Hospital
- Principal Investigator: Hans Christian Hoeck, DmSci, Center for Clinical and Basic Research
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bressendorff I, Brandi L, Schou M, Nygaard B, Frandsen NE, Rasmussen K, Odum L, Ostergaard OV, Hansen D. The Effect of High Dose Cholecalciferol on Arterial Stiffness and Peripheral and Central Blood Pressure in Healthy Humans: A Randomized Controlled Trial. PLoS One. 2016 Aug 10;11(8):e0160905. doi: 10.1371/journal.pone.0160905. eCollection 2016.
- Nygaard B, Frandsen NE, Brandi L, Rasmussen K, Oestergaard OV, Oedum L, Hoeck HC, Hansen D. Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial. PLoS One. 2014 Aug 28;9(8):e102965. doi: 10.1371/journal.pone.0102965. eCollection 2014.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
August 3, 2009
First Submitted That Met QC Criteria
August 4, 2009
First Posted (Estimate)
August 6, 2009
Study Record Updates
Last Update Posted (Estimate)
August 24, 2011
Last Update Submitted That Met QC Criteria
August 23, 2011
Last Verified
August 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7. juli 2009, version 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.